Results 271 to 280 of about 157,671 (305)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2001
ZD-0473 (formerly JM-473 and AMD-473) is a sterically hindered platinum (II) complex designed and synthesized by Johnson Matthey Technology and the Cancer Research Campaign (CRC) and under development as a potential treatment for cisplatin-resistant cancer. AstraZeneca is developing both an i.v. and an oral formulation of ZD-0473.
openaire +1 more source
ZD-0473 (formerly JM-473 and AMD-473) is a sterically hindered platinum (II) complex designed and synthesized by Johnson Matthey Technology and the Cancer Research Campaign (CRC) and under development as a potential treatment for cisplatin-resistant cancer. AstraZeneca is developing both an i.v. and an oral formulation of ZD-0473.
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2004
ZD-6474, one of a series of inhibitors of vascular endothelial growth factor receptor tyrosine kinase, which also has activity against the epidermal growth factor receptor tyrosine kinase, is under development by AstraZeneca for the potential treatment of solid tumors.
openaire +1 more source
ZD-6474, one of a series of inhibitors of vascular endothelial growth factor receptor tyrosine kinase, which also has activity against the epidermal growth factor receptor tyrosine kinase, is under development by AstraZeneca for the potential treatment of solid tumors.
openaire +1 more source
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Nature Reviews Drug Discovery, 2014Ruth March
exaly